Highlights d LAG-3 expression identifies natural regulatory plasma cells d LAG-3 + CD138 hi plasma cells express IL-10 within hours of stimulation d LAG-3 + CD138 hi plasma cells have a unique epigenome poised to express IL-10 d LAG-3 + CD138 hi plasma cells develop via an antigen-specific mechanism
In Brief
Plasma cells secrete antibodies and play a key role in host defense against infection. Lino et al. identify a novel subset of natural regulatory plasma cells characterized by the expression of LAG-3 that develops at steady state independently of microbiota, and respond to innate stimulation by producing immunosuppressive IL-10.
INTRODUCTION
The immune system protects the host from infectious diseases and helps to remove its damaged components. Its activity is controlled by stimulatory and inhibitory forces. Inhibitory pathways are important to prevent its spontaneous hyperactivation and to regulate established immune reactions.
B lymphocytes have emerged as important players in the negative regulation of immunity via the production of interleukin-10 (IL-10) and IL-35 (Fillatreau et al., 2002; Shen and Fillatreau, 2015) . This B cell function has noticeable effects in autoimmune, allergic, infectious, and malignant diseases (Shen and Fillatreau, 2015) . The phenomenology of B cell-mediated suppression is well established, yet the B cells mediating these activities in vivo remain incompletely defined. Their identification has been approached by isolating known B cell subsets and assessing their capacity to produce IL-10 in vitro and to suppress immunity in recipient mice upon adoptive transfer. B cells expressing high amounts of CD1d, including marginal zone B cells and transitional T2-like B cells, as well as B1a cells and Tim-1 hi B cells, have the capacity to suppress immunity in an IL-10dependent manner in such assays (Blair et al., 2009; Yanaba et al., 2008; Yang et al., 2012) . However, only a fraction of the cells within these subsets express IL-10 after activation in vitro, even when strong pharmacological agents such as ionomycin and phorbol myristate acetate (PMA) are used, and the phenotype of the B cells actually producing IL-10 in vivo in the recipient is not defined after transfer. Other studies have used IL-10 reporter mice to identify IL-10-producing cells ex vivo without re-stimulation. These have revealed CD138 hi plasmocytes (plasmablasts and plasma cells) as the major source of B cell-derived IL-10 in vivo in autoimmune, infectious, and malignant diseases (Matsumoto et al., 2014; Neves et al., 2010; Shalapour et al., 2015; Shen et al., 2014; Teichmann et al., 2012) . A hypothesis reconciling these findings could be Mice were infected i.v. with Salmonella (SL7207, 10 7 CFU), and plasmocytes characterized in spleen on day 1 p.i. (A) mRNA amounts for receptors overexpressed in IL-10 + compared with IL-10 À plasmocytes from Il10eGFP mice. Microarrays in triplicate. Expression amounts normalized using GCRMA are shown (Log2 transformed). Lag3 is expressed 9.4-fold higher in Il10eGFP + CD138 hi than Il10eGFP À CD138 hi cells.
(legend continued on next page) that B cell-mediated regulation is an inducible function acquired by B cells such as CD1d hi B cells upon activation and differentiation into IL-10-or IL-35-producing plasmocytes.
Here, we addressed whether IL-10-producing plasmocytes defined a separate subset using a model of infection by the bacterium Salmonella Typhimurium. In this model, B cell-derived IL-10 is produced exclusively by plasmocytes that emerge before day 1 post-infection (p.i.) and leads to a rapid modulation of immunity to Salmonella (Neves et al., 2010) . We reasoned that the rapidity of this response would facilitate the identification of the precursors of immunosuppressive IL-10-producing plasmocytes without having to recourse to adoptive transfer protocols susceptible to creating non-physiological cellular responses.
RESULTS

LAG-3 Identifies IL-10-Expressing Plasma Cells in Infected Mice
Salmonella infection results in the rapid appearance of IL-10 + CD138 hi cells. To assess whether these cells defined a particular subset, we compared their transcriptome to the one of IL-10 À CD138 hi cells from Il10eGFP mice on day 1 p.i. This yielded 22 genes coding for transmembrane receptors overexpressed in IL-10 + cells ( Figure 1A) , including lymphocyte-activation gene 3 (Lag3; CD223) that was previously identified as a marker for IL-10-producing T regulatory type (Tr1) cells (Gagliani et al., 2013) .
LAG-3 protein was found on most IL-10 + CD138 hi cells on day 1 p.i., and IL-10 was expressed uniformly in LAG-3 + CD138 hi cells ( Figure 1B ). LAG-3 was not detected on CD19 + CD138 À cells (Figure S1A) . This staining was specific because it was not observed on Lag3 À/À plasma cells ( Figure S1B ). Consistently, Il10 mRNA was predominantly expressed in LAG-3 + CD138 hi cells compared to other B cell subsets in infected C57BL/6 mice ( Figure 1C ). IL-10 + LAG-3 + CD138 hi cells displayed typical plasma cell features including a plasmacytoid morphology ( Figure 1D ), the spontaneous secretion of antibodies ( Figure 1E ), a non-proliferative state ( Figure 1F ), and an elevated expression of BLIMP-1 ( Figure 1G ). LAG-3 + CD138 hi cells also differed from LAG-3 À CD138 hi cells in their higher expression of CD1d and CD200, as well as their lower expression of B220, MHC-II, CD43, CD71, and Fas ( Figure 1H ).
We conclude that LAG-3 + CD138 hi plasma cells define the main population of IL-10-expressing B cells in infected mice.
LAG-3 + CD138 hi Plasma Cells Develop Independently of Microbe-Derived Signals in Naive Mice
The non-proliferating status of IL-10 + LAG-3 + CD138 hi cells was unexpected because B cell differentiation into plasma cell nor-mally requires cell proliferation over several days. This led us to hypothesize that LAG-3 + CD138 hi cells were already present in naive mice. Indeed, LAG-3 + CD138 hi cells were detected in the spleen, bone marrow (BM), and mesenteric lymph nodes (mLN) of naive mice (Figures 2A and S2A) . They had the key attributes of plasma cells such as high BLIMP-1 expression (Figures 2B and S2B) , a plasmacytoïd morphology ( Figure 2C ), and the spontaneous secretion of antibodies ( Figure 2D ). In contrast to proliferating LAG-3 À CD138 hi plasmablasts, LAG-3 + CD138 hi cells were non-proliferative and produced mostly IgM (Figures 2D and 2E) . These features of LAG-3 + CD138 hi cells therefore did not change between day 0 and day 1 p.i., except for the induction of IL-10 expression after challenge ( Figure 2F ). LAG-3 + CD138 hi cells also differed from LAG-3 À CD138 hi cells in their higher expression of CD1d, CD69, CD81, CD200, and CD273 (PD-L2), as well as their lower expression of B220, MHC-II, CD43, CD71, FAS, and CXCR3 in naive mice ( Figure 2G ). PD-L1 was highly expressed by both plasmocyte subsets. LAG-3 + CD138 hi cells expressed surface IgM, CD79a, and CD79b ( Figure 2G ). LAG-3 expression was not observed on B cells ( Figure S2C ).
Plasma cells are normally induced upon foreign antigen stimulation. LAG-3 + CD138 hi cells, however, were present in similar numbers in germ-free and specific-pathogen-free mice (Figure 2H) . These cells are therefore generated via an endogenous response. Their number increased markedly in aging mice (Figures 2I and S2D) .
We conclude that, in naive mice, LAG-3 + CD138 hi cells are a subset of natural plasma cells mainly producing IgM.
LAG-3 + CD138 hi Cells Rapidly Upregulate IL-10 after Infection IL-10 expression in CD138 hi cells increased already at 3 hr p.i. compared to naive mice (p = 0.0009; unpaired t test) ( Figure 3A ). IL-10 was expressed predominantly in LAG-3 + CD138 hi cells during the first 24 hr p.i. ( Figure 3A ). IL-10 is thus programmed for a rapid expression in LAG-3 + CD138 hi cells, whose numbers were similar at day 0 and day 1 p.i. ( Figure 3B ). As expected, IL-10 and LAG-3 were not detected in CD19 + CD138 À B cells ( Figure S3A ).
The immediate upregulation of IL-10 in LAG-3 + CD138 hi cells led us to compare the capacity of CD138 hi cells and other B cell subsets to produce IL-10 in vitro. CD138 hi plasmocytes secreted markedly more IL-10 than CD1d hi CD19 + B cells (Figure 3C) , and their IL-10 production derived mostly from LAG-3 + CD138 hi cells ( Figure 3C ).
We then examined IL-10 expression at later time points p.i. during the extra-follicular response. The number of CD138 hi cells increased progressively p.i., and they represented 10% of all (B) Flow cytometry plots showing IL-10 and LAG-3 expression in CD138 hi cells (left); frequency of LAG-3 + in IL-10 + CD138 hi cells (middle); expression of IL-10 in B cells (CD19 + CD138 À ) and LAG-3 + CD138 hi cells (right). Representative of six experiments. (C) Il10 mRNA expression in isolated subsets from C57BL/6 mice. Pool of two experiments. (D) Transmission electron microscopy images of plasmocytes from Il10eGFP mice. Scale bar is 2 mM. (E) Frequencies of antibody-secreting cells (ASCs) in IL-10 + CD138 hi and IL-10 À CD138 hi cells from Il10eGFP mice by ELISPOT. Pool of three experiments. (F) Flow cytometry plots of LAG-3 and Ki67 expression in CD138 hi cells from C57BL/6 mice. Representative of four experiments. (G) Flow cytometry plot of LAG-3 and BLIMP-1 in BLIMP-1 + CD138 hi cells (left), and amounts of BLIMP-1 (MFI) in B cells and plasmocytes in Prdm1eGFP mice (n = 4) (right). Representative of two experiments. (H) Surface molecules expression on LAG-3 + CD138 hi (red), LAG-3 À CD138 hi (blue), and CD19 + CD138 À B cells (gray) from C57BL/6 mice. Representative of two experiments. Data show mean ± SEM ( ns p > 0.05, **p < 0.01). See also Figure S1 . splenocytes on day 8 p.i. (Figures 3D and S3B ). This increase reflected the accumulation of LAG-3 À CD138 hi cells, while IL-10 + LAG-3 + CD138 hi cells did not expand greatly after day 1 p.i. ( Figure 3D ). IL-10 expression was associated with LAG-3 + CD138 hi cells at all time points ( Figure S3C ). The frequencies of LAG-3 + and IL-10 + cells within CD138 hi cells sharply decreased from day 1 p.i. onward ( Figure 3D ). These results emphasize the unique response dynamics of IL-10 + LAG-3 + CD138 hi cells. Because LAG-3 has been implicated in the regulation of humoral immunity (Butler et al., 2011) , we asked whether LAG-3 expressed on CD138 hi cells modulated the plasmocyte response p.i. To this end, we crossed Lag3 À/À mice on an Il10eGFP background and generated mixed bone marrow chimera in which only B cells lacked Lag3 but could express Il10eGFP. A LAG-3 deficiency in plasma cells did not alter the number of IL-10 + CD138 hi cells p.i., yet led to an increased accumulation of IL-10 À CD138 hi cells ( Figure 3E ). Thus, LAG-3 + CD138 hi cells control the expansion of LAG-3 À CD138 hi cells in a LAG-3-dependent manner. An important property of the adaptive immune system is immunological memory. To assess whether LAG-3 + CD138 hi cells acquire features of memory B cells, we compared their response in vaccinated and naive mice p.i. As expected, vaccinated mice better controlled Salmonella than naive mice (Figure S3D) . IL-10 and LAG-3 expression in CD138 hi cells were comparable in the two groups p.i. (Figures 3F and 3G ). Thus, LAG-3 + CD138 hi cells did not display the typical sign of an amplified response upon rechallenge. IL-10 + CD138 hi cells isolated from vaccinated mice on day 1 p.i. produced mostly IgM (Figure 3H) , indicating that they had not undergone isotype switching away from IgM, unlike what is observed in classical memory B cell responses.
These data show that LAG-3 + CD138 hi cells can rapidly upregulate IL-10 expression without dividing, and inhibit the expansion of LAG-3 À CD138 hi cells p.i.
LAG-3 + CD138 hi Cells Have a Unique Plasma Cell Epigenome
We next examined the hypothesis that LAG-3 + CD138 hi cells were a distinct subset of plasma cells epigenetically poised to rapidly produce IL-10. To this end, we compared the genome-wide DNA-methylomes of LAG-3 + CD138 hi cells, LAG-3 À CD138 hi cells, and peripheral B cell subsets from naive mice. In addition, we included LAG-3 + CD138 hi , LAG-3 À CD138 hi , IL-10 + CD138 hi , and IL-10 À CD138 hi cells isolated at day 1 p.i.
Genome-wide DNA-methylation profiling was performed by reduced representation bisulfite sequencing (RRBS) covering on average 3-4 million CpG sites per sample. An unsupervised principal component analysis (PCA) placed LAG-3 + CD138 hi and IL-10 + CD138 hi cells at a distinctive position relative to LAG-3 À CD138 hi and IL-10 À CD138 hi cells, as well as to other B cell subsets, underlying their unique methylome profile. The position of LAG3 + CD138 hi cells taken at day 0 and day 1 p.i. was similar and showed a striking co-localization with IL-10 + CD138 hi cells ( Figure 4A ), underlining the intimate relationship between these subsets. The various groups of CD138 hi cells localized at the same position on PC1, which separated B cells from plasma cells. In keeping with the described hypomethylation of plasma cells' genome (Kulis et al., 2015) , the various CD138 hi subsets analyzed here displayed the lowest degree of genome-wide methylation ( Figure S4A ). Thus, LAG-3 + CD138 hi and IL-10 + CD138 hi cells have a plasma cell epigenetic profile but with unique features. A pairwise comparison of LAG-3 + CD138 hi and LAG-3 À CD138 hi cells from naive mice identified 469 differentially methylated regions (DMRs) showing a genome-wide distribution ( Figure S4B ). In a hierarchical analysis, these DMRs separated CD138 hi cells and B1 cells away from the other B cell subsets ( Figure 4B ), with LAG-3 + CD138 hi cells showing the highest similarity to B1a cells (Figures 4B and S4C) . A particular cluster of DMRs was found at the Il10 locus. IL-10 + CD138 hi cells, LAG-3 + CD138 hi cells, and B1a cells not only exhibited the lowest overall degree of DNA methylation at the Il10 locus ( Figure 4C ) but also shared distinct patterns of hypomethylated regions around the Il10 gene. Many of these hypomethylated sites overlapped with B cell-specific DNase hypersensitive sites, indicating an epigenetic ''preprogrammed'' open chromatin state of Il10 in IL-10 + CD138 hi , LAG-3 + CD138 hi , and B1a cells (Figures 4D and S4D) . Of note, IL-10 + CD138 hi cells, LAG-3 + CD138 hi cells, and B1a cells also showed a preferential epigenetic relationship at the 469 DMR ( Figure S4E ).
In summary, LAG-3 + CD138 hi cells are the epigenetically primed precursors of IL-10 + LAG-3 + CD138 hi cells and show a distinct plasma cell-specific epigenome with the Il10 locus primed for expression and features reminiscent of B1a cells.
Transcriptional Properties of LAG-3 + CD138 hi Cells
We next determined the transcriptomes of LAG-3 + CD138 hi and LAG-3 À CD138 hi cells on day 0 and day 1 p.i by mRNaseq. These analyses identified 648 differentially expressed genes (DEGs) (pval % 0.01; FDR % 0.05) on day 0 and 2,280 on day 1 p.i. ( Figure S4F ). A hierarchical clustering with all DEGs confirmed the relative proximity of LAG-3 + CD138 hi cells from naive mice and day 1 p.i. compared to LAG-3 À CD138 hi cells ( Figure 4E ). The top DEGs (Tables S1 and S2) included genes coding for IL-10 and the surface proteins LAG-3, CD200, and CXCR3, whose differential expression was also reflected in protein amount (Figures 1 and 2) . A Gene Set Enrichment Analysis (MSigDB) of the 648 DEGs in naive mice highlighted cell cycle regulation as the major pathway discriminating the LAG3 À and LAG3 + subsets ( Figure S4G ). 23 of the 648 DEGs were also differentially methylated between LAG-3 + CD138 hi and LAG-3 À CD138 hi cells, including Il10, Bcl2, Zfp36l1, Irf8, and other B cell regulators ( Figure 4F ). This argues for an epigenetically primed control of their expression. We finally focused on transcription regulators differentially expressed in higher (or lower) amount on both day 0 and 1 p.i. in LAG-3 + CD138 hi cells as compared to LAG-3 À CD138 hi cells. We identified 22 factors (including transcription factors and co-factors, gene expression regulators, and general DNA binding proteins) with higher expression in LAG-3 + CD138 hi cells and 8 factors with higher expression in LAG-3 À CD138 hi cells ( Figure 4G ). LAG-3 + CD138 hi cells showed a higher expression of Klf4, Bhlhe40, and Bmyc that are involved in the inhibition of proliferation, and of Hes1 that indicates higher Notch signaling activity. They also displayed a higher expression of Fos, Junb, Egr1, Egr2, Cebpb, Irf8, and Satb1 ( Figures 4G and 4H ), i.e., genes coding for factors for which we found predicted binding sites in the Il10, Lag3, Cd200, and Cd273 (PD-L2) loci ( Figure 4H ). FOS, JUN-B, and EGR-2 drive IL-10 expression in other immune cells (Iwasaki et al., 2013; Wang et al., 2005; Yoshida et al., 2012) . EGR2 was also important in CD4 + T cells for LAG-3 expression, BLIMP-1-mediated induction of IL-10, and their regulatory activity (Iwasaki et al., 2013) . The reduced expression of Foxm1 in LAG-3 + CD138 hi cells ( Figures 4G and 4H ) might be linked to two effects: their lack of proliferation (Chen et al., 2013) and the control of Il10 transcription since Foxm1 binding sites were predicted in this locus ( Figure 4H ).
We conclude that LAG-3 + CD138 hi cells exhibit a distinct transcriptome, partially linked to epigenetic changes, keeping them in a quiescent state primed for IL-10 expression. This molecular (E) mRNA expression for the 3,631 DEGs that distinguish LAG-3 + CD138 hi and LAG-3 À CD138 hi cells on day 0 and 1 p.i. (see Figure S4F ). (F) mRNA expression and local DNA methylation for genes both differentially expressed and methylated between LAG-3 + CD138 hi and LAG-3 À CD138 hi cells from naive mice. (G) Transcription regulators expressed at higher (top) or lower (bottom) amounts on both day 0 and 1 p.i. in LAG-3 + CD138 hi compared to LAG-3 À CD138 hi cells.
(H) Expression of transcription regulators differentially expressed between LAG-3 + CD138 hi cells and LAG-3 À CD138 hi cells (see G) with predicted binding motif in either the Il10, Lag3, Cd200, or Cd273 loci. Row z-scores for expression are based on log 10 (rpkm+1), and for DNA methylation on DNA methylation frequency (%). Samples were from naive mice (A, C, D, E, G, H) except where indicated. See also Figure S4 .
program could explain why only this subset of plasmocytes expresses IL-10 and other immune checkpoint receptor molecules.
BCR Repertoire and Developmental Origin of LAG-3 + CD138 hi Cells
The differentiation of B cells into plasma cells requires the engagement of their BCR by antigen. Our observation that LAG-3 + CD138 hi cells develop independently of the microbiota prompted us to examine whether they express a particular BCR repertoire.
Single-cell analysis of their IgH and Igk revealed that LAG-3 + CD138 hi cells and IL-10 + CD138 hi cells displayed a lower utilization of IgH VH1-81 and a higher usage of VH7, VH10, and VH11 segments compared to LAG-3 À CD138 hi cells and IL-10 À CD138 hi cells ( Figures 5A and S5A ). The majority of VH11 + IgH were associated with a Vk14.126 + (formerly Vk9) Igk (Figure 5B) , forming a combination typical of B1a cells (Hardy et al., 2004) . Flow cytometry analyses confirmed the presence of a VH11 + Vk14.126 + BCRs on splenic LAG-3 + CD138 hi cells and IL-10 + CD138 hi cells but not on LAG-3 À CD138 hi cells or IL- in VH11 + Vk14.126 + cells ( Figure 5E ). Thus, some LAG-3 + CD138 hi and IL-10 + CD138 hi cells carry a VH11 + Vk14.126 + BCRs typical of B1a cells ( Figures S5C and S5D ). However, the other VH segment classically associated with B1a cells, namely VH12, was not found in spleen LAG-3 + CD138 hi cells, and only on about 1% of BM IL-10 + CD138 hi cells ( Figure 5F ). The VH11 + IgH from LAG-3 + CD138 hi and IL-10 + CD138 hi cells had few mutations as well as N-additions, and a large proportion contained the CDR3 characteristic of the anti-phosphatidylcholine (PtC) response ( Figures S5E and S5F) . Accordingly, nearly all VH11 + Vk14.126 + cells displayed reactivity against PtC (Figure 5G ), and about 2% of splenic LAG-3 + CD138 hi cells as well as 26% of BM IL-10 + CD138 hi cells in naive mice reacted toward this particular antigen ( Figure 5H ). In BM, more than 80% of PtCreactive CD138 hi cells expressed IL-10 ( Figure S5G ). Taken together, these data strongly suggest that VH11 + Vk14.126 + LAG-3 + CD138 hi spleen and BM cells derive from B1a cells. Some LAG-3 + CD138 hi cells expressing other BCR might also derive from B1a cells because LAG-3 + CD138 hi and IL-10 + CD138 hi cells had overall fewer IgH somatic mutations than LAG-3 À CD138 hi and IL-10 À CD138 hi cells ( Figure 5I ). This correlated with a lower AID fate-mapping marking of LAG-3 + CD138 hi cells ( Figure 5J ). Furthermore, a higher proportion of IgH from LAG-3 + CD138 hi and IL-10 + CD138 hi lacked both somatic mutation and N-addition as compared to LAG-3 À CD138 hi and IL-10 À CD138 hi cells ( Figure 5K ). Nonetheless, some LAG-3 + CD138 hi and IL-10 + CD138 hi cells expressed IgH sequences with mutations and N-additions ( Figure 5L ), suggesting an additional origin for LAG-3 + CD138 hi cells.
To evaluate the capacity of various B cell subsets to generate LAG-3 + CD138 hi cells, we adoptively transferred B1a, B1b, and B2 cells from peritoneal cavity (PeC) as well as splenic B cells into Rag2 À/À mice ( Figure 5M ). The analysis of the recipient mice confirmed that several B cell subsets could give rise to LAG-3 + CD138 hi cells, as observed also upon culture of B cell subsets in vitro ( Figure S5H ). Marginal zone B cells were not a non-redundant source of LAG-3 + CD138 hi cells in vivo since mice that lacked marginal zone B cells due to a B cell-restricted deficiency in NOTCH2 (Saito et al., 2003) displayed normal frequency of LAG-3 + CD138 hi cells ( Figure S5I ) despite their globally reduced numbers of splenic plasmocytes (data not shown). To further delineate the origin of LAG-3 + CD138 hi cells in a physiological context, we next developed a fate mapping system using the fact that B1a cells poorly expressed CD21 compared to other B cell susbsets, and crossed Cd21-cre mice to ROSA-STOP-eYFP reporter mice. In Cd21-cre-ROSA-STOP-eYFP mice, most B1a cells were eYFP À in PeC, spleen, and BM, which was even more apparent when focusing on the VH11 + Vk14 + fraction of B1a cells ( Figure 5N ). In contrast, B1b and B2 cells from PeC as well as follicular and marginal zone B cells from spleen were mostly eYFP + ( Figure 5N ). The LAG-3 + CD138 hi cell subset contained an intermediate frequency of eYFP À cells, underlining their heterogeneous origin. Importantly, the LAG-3 + CD138 hi cells that carried a VH11 + Vk14 + BCR were largely eYFP À , indicating that eYFP À B1a cells did not switchon eYFP expression during their differentiation into LAG-3 + CD138 hi cells ( Figure 5N ).
We conclude that LAG-3 + CD138 hi cells develop from several B cell subsets via a mechanism involving the BCR since they have a distinct BCR repertoire.
Roles of BCR and TLR in LAG-3 + CD138 hi Plasma Cell Development and Function
We next examined how the BCR influenced the accumulation of LAG-3 + CD138 hi cells in naive mice and their upregulation of IL-10 after challenge.
The Bruton tyrosine kinase (Btk) is essential for BCR signaling (Corneth et al., 2016) . Btk À/À mice showed a developmental defect in B1a cells but not in B1b cells and marginal zone B cells ( Figure 6A ). They also displayed reduced frequencies and numbers of LAG-3 + CD138 hi cells ( Figure 6A ). We next assessed the effect of the BCR co-receptors CD19 and CD72 for the generation of LAG-3 + CD138 hi cells. We also studied mice genetically deficient in proteins involved in antigen presentation Figure 5 . BCR Repertoire of LAG-3 + and IL-10 + Plasmocytes (A) Frequency of Igh containing VH1-81 (left) or VH11 (middle) in spleen LAG-3 + CD138 hi (n = 253), LAG-3 À CD138 hi (n = 150), Il10eGFP + CD138 hi (n = 181), and Il10eGFP À CD138 hi (n = 121) cells on day 0 and day 1 p.i. (SL7207; 10 7 CFU). Frequency of LAG-3 + in VH11 + CD138 hi and VH11 À CD138 hi spleen cells of naive mice (n = 12) (right). (B) Frequency of Vk14.126 + cells in VH11 + cells for spleen and BM cells described in Figure S5A (I) Mutations in IgH sequences (naive BM Il10eGFP + CD138 hi , n = 165; Il10eGFP À CD138 hi , n = 151; naive spleen LAG-3 + CD138 hi , n = 231; LAG-3 À CD138 hi , n = 129; day 1 spleen Il10eGFP + CD138 hi , n = 155; Il10eGFP À CD138 hi , n = 108) (left). Number of somatic mutations per sequence for mutated IgH (LAG-3 + CD138 hi cells, n = 31; LAG-3 À CD138 hi cells, n = 19) (right). (CD1d), innate immune signaling (MyD88 and TRIF), T cell:B cell interaction (CD40, T cell receptor for antigen), and inflammation (NOS2, IL-10) ( Figure 6B ). LAG-3 + CD138 hi cells were present in lower amounts in mice deficient for CD19, which is a positive regulator of BCR signaling, and in higher numbers in mice lacking CD72, which is an inhibitory BCR co-receptor. In contrast, they were normally present in Myd88 À/À Trif À/À mice, which lacked TLR signaling. Mice deficient in CD40 or abTCR-expressing T cells also generated these cells normally. LAG-3 + CD138 hi cells can therefore develop independently of canonical T cell:B cell interactions and are thus not strictly dependent on a T cell-dependent antigen. The finding that BCR but not TLR signaling contributed to the formation of LAG-3 + CD138 hi cells led us to assess whether mice with a restricted BCR repertoire had an altered abundance of these plasma cells. Indeed, B1-8i mice carrying a fixed IgH chain on an Igk-deficient background displayed a 2-fold reduction in the frequency of LAG-3 + CD138 hi cells compared to controls ( Figure 6C ). Of note, antibodies cloned from LAG-3 + CD138 hi cells displayed (B) Numbers and frequencies of LAG-3 + CD138 hi cells in CD138 hi plasmocytes in spleen of naive C57BL/6 (n = 40), Cd19 À/À (n = 5), Il10 À/À (n = 8), Tcrab À/À (n = 7), Cd72 À/À (n = 10), Cd1d À/À (n = 6), Myd88 À/À (n = 10), Myd88 À/À Trif À/À (n = 12), Cd40 À/À (n = 6), Nos2 À/À (n = 10), and Fcgr2b À/À (n = 5) mice.
(C) Frequencies of LAG-3 + in spleen CD138 hi cells of B1-8iIgk À/À and WT mice. Pool of two experiments (n = 4-5).
(D) Frequency of IL-10 in spleen LAG-3 + CD138 hi of Il10eGFP mice 24 hr after i.v. injection of indicated reagents. Pool of three experiments (n = 6). Data show mean ± SEM ( ns p > 0.05, *p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001). See also Figure S6 .
little polyreactivity when tested as recombinant molecules in ELISA (Tiller et al., 2009 ), unlike those from BM IL-10 À IgM + CD138 hi cells ( Figure S6A ). Considering that BCR signaling contributed to the development of LAG-3 + CD138 hi cells at steady state, we next asked whether such cells could be generated upon immunization with 4-hydroxy-3-nitrophenylacetyl keyhole limpet hemocyanin (NP-KLH), NP-Ficoll, or NP-LPS i.e., classical T cell-dependent, T cell-independent type II, and T cell-independent type I antigens, respectively ( Figure S6B ). These immunizations induced NP-reactive LAG-3 À CD138 hi cells, but not NP-reactive LAG-3 + CD138 hi cells. We conclude that LAG-3 + CD138 hi cells develop from B cells at steady state upon a particular form of BCR engagement that is not recapitulated by these immunizations.
We next asked whether BCR or other signals controlled the upregulation of IL-10 expression in LAG-3 + CD138 hi cells after challenge. To this end, Il10eGFP mice were injected intravenously with anti-BCR, anti-CD40, or LPS, alone or in combination ( Figure 6D ). The administration of anti-BCR or anti-CD40 had no effect on IL-10 expression, yet LPS induced a strong upregulation of IL-10 in LAG-3 + CD138 hi cells. These results demonstrated that IL-10 expression was induced in a polyclonal manner in LAG-3 + CD138 hi cells upon TLR4 stimulation. This was in agreement with the fact that LAG-3 + CD138 hi cells from naive mice, as well as of LAG-3 + CD138 hi cells and IL-10 + CD138 hi cells from day 1 p.i., had comparable frequencies of VH11 + Vk14 + cells ( Figure 5C ), suggesting that IL-10 was induced in LAG-3 + CD138 hi cells in a polyclonal manner.
We conclude that the development of LAG-3 + CD138 hi cells is controlled by the BCR and independent of TLR signaling as well as T cell help, while their upregulation of IL-10 after challenge is determined by TLR signaling.
Elevated Abundance of LAG-3 + CD138 hi Cells Correlates with Impaired Immunity against Salmonella An ablation of IL-10 production by CD138 hi plasmocytes increased host defense to Salmonella (Neves et al., 2010) . Here, we sought to determine how an increased abundance of LAG-3 + CD138 hi cells affected host resistance to this infection using Cd72 À/À mice.
Cd72 À/À mice had an increased number of LAG-3 + CD138 hi cells, while other B cell subsets did not display any major defect ( Figure S7A ). The increased accumulation of LAG-3 + CD138 hi Groups were compared using two-tailed unpaired t test ( ns p > 0.05, *p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001). Survival curves were compared using Wilcoxon test, **p < 0.01, ****p < 0.0001. Data show mean ± SEM. See also Figure S7 . cells in Cd72 À/À mutants was confirmed with littermate mice ( Figure S7A ). After infection, Cd72 À/À mice displayed an increased accumulation of IL-10 + CD138 hi and LAG-3 + CD138 hi cells ( Figures 7A and S7B) , an impaired control of the infection (Figure S7C) , and a reduced survival ( Figure 7B ) compared to controls. The CD72 deficiency had no effect in B cell-deficient mice, confirming that the observed differences were due to the lack of Cd72 in B cells ( Figure S7D ). To validate the inhibitory impact of IL-10 on host defense in Cd72 À/À mice, mice were treated intravenously with a combination of anti-IL-10 and anti-IL-10 receptor. This significantly improved the control of the bacteria ( Figure 7C ). Since LAG-3 + CD138 hi cells are the major source of IL-10 after infection, this supports the notion that LAG-3 + CD138 hi cells inhibit host defense through IL-10 provision.
Finally, we investigated how CD72 deficiency affected the host response to secondary infection. Il10eGFP and Cd72 À/À Il10eGFP mice were vaccinated and later challenged with Salmonella. Mice lacking Cd72 displayed a higher accumulation of IL-10 + CD138 hi cells and LAG-3 + CD138 hi cells upon re-challenge, while LAG-3 À CD138 hi and total CD138 hi cells were present in comparable numbers in the two groups of mice (Figures 7D, 7E, and S7E) . Consistently, CD72 deficiency led to higher bacterial load and reduced survival ( Figure 7F) , compromising vaccine efficacy. Memory T helper 1 (Th1) cells play a major role in vaccine-induced protection against Salmonella. In vaccinated Cd72 À/À mice, numbers of memory Salmonella-reactive Th1 CD4 + T cells in the BM were reduced ( Figures 7G and S7F) , and accumulation of exhausted PD-1 + CD4 + T cells, PD-1 + CD8 + T cells, and regulatory Foxp3 + CD4 + T cells were increased ( Figures 7H and S7G) .
These data demonstrate that in the absence of CD72, a higher accumulation of LAG-3 + CD138 hi plasma cells is associated with impaired immunity to Salmonella.
DISCUSSION
This study demonstrates the existence of natural regulatory plasma cells, which are the major source of IL-10 early after infection with Salmonella.
An unexpected finding was that the cells expressing IL-10 were not reactive plasmablasts but instead resident plasma cells. Upon activation, B cells successively generated antibody-secreting plasmablasts that proliferated and then plasma cells that did not divide and expressed higher amounts of the transcription factor BLIMP-1. LAG-3 + CD138 hi cells were nonproliferating and expressed higher amounts of BLIMP-1 than LAG-3 À CD138 hi cells, thus qualifying as bone fide plasma cells. Their non-dividing status correlated with the lack of expression of factors necessary for cell division including the transferrin receptor CD71 and the transcriptional regulator Foxm1, as well as the increased expression of the cell proliferation inhibitors Egr2, Zfp36l1, Pdcd4, Klf4, and Bhlhe40. KLF4 is absent in plasmablasts generated in vitro but is expressed in long-lived BM plasma cells (Schoenhals et al., 2016) . LAG-3 + CD138 hi cells thus display a profile of mature plasma cells, while retaining the capacity to respond to external stimuli, in particular TLR, via the production of IL-10.
LAG-3 + CD138 hi plasma cells expressed several immune checkpoint receptors implicated in the negative regulation of immunity such as LAG-3, PD-L1, PD-L2, and CD200. LAG-3 is a co-inhibitory receptor related to CD4 and implicated in the down-modulation of T cell immunity. The co-expression of several inhibitory molecules is important because these molecules usually act synergistically, so that their combined blockade achieves greater effect than the neutralization of single molecules. Blockade of LAG-3 and PD-L1 augments immunity toward Plasmodium falciparum by amplifying T cell activation and antibody production (Butler et al., 2011) . Here, we found that LAG-3 on plasma cells did not influence their IL-10 expression, but inhibited the accumulation of IL-10 À CD138 hi cells, which were LAG-3 À , early after infection. The suppressive function of LAG-3 + CD138 hi cells therefore extends beyond IL-10 production, suggesting a more global role in immune regulation.
LAG-3 + CD138 hi cells developed from several B cell subsets in a BCR-dependent manner. Their preserved accumulation in germ-free mice suggests that they are selected on self-antigens.
Our study has not identified the antigens involved in the generation of LAG-3 + CD138 hi cells. Since these cells increased with age, which has also been associated with an accumulation of damaged cells (Baker et al., 2016) , it is tempting to speculate that LAG-3 + CD138 hi cells react toward antigens released by damaged cells. This hypothesis is consistent with the recognition by natural IgM of senescent cells (Frescas et al., 2017) and by natural antibodies binding PtC of apoptotic cells (Shaw et al., 2000) . LAG-3 + CD138 hi cells may thus provide a feedback mechanism, which senses the number of damaged cells and proportionally downregulates the activation of immunity to limit additional and potentially excessive immunopathology when an immune stimulus arises. Mice lacking the BCR inhibitory co-receptor CD72 had an increased abundance of LAG-3 + CD138 hi cells and an impaired capacity to control Salmonella infection. The induction of IL-10 in LAG-3 + CD138 hi cells was primarily controlled by TLR. We cannot, however, exclude that BCR signaling played a role in IL-10 production, even if it was not the major switch for IL-10 expression. For instance, it might contribute to the transcription of Il10 in LAG-3 + CD138 hi cells at steady state in naive mice and synergize with TLR to upregulate IL-10 expression after challenge. It is indeed possible that these cells express BCR that recognize endogenous antigens already available at steady state and persisting during challenge.
In conclusion, natural regulatory plasma cells can rapidly provide a first layer of B cell-mediated immune regulation in response to TLR signals. They might subsequently be complemented by other subsets of suppressive B cells and plasma cells induced in an antigen-specific manner.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice C57BL/6, Il10eGFP (Neves et al., 2010) , Btk À/À , Cd72 À/À , Cd19 À/À , Cd1d À/À , Nos2 À/À , Rag2 À/À , B1-8iIgk À/À , Fcgr2b À/À , Cd19-cre-Notch2 fl/fl , Il10 À/À , Lag3 À/À (Miyazaki et al., 1996 , Workman et al., 2004 , Tcra/b À/À , Cd40 À/À , Myd88 À/À , Myd88 À/À Trif À/À , J H T, Cd72 À/À J H T, Prdm1eGFP, Cd72 À/À Il10eGFP, Lag3 À/À Il10eGFP, Cd21-cre-ROSA-STOP-eYFP, Aicda-cre-ERT2-ROSA-STOP-RFP, C3H/HeOuJ were bred under specific pathogen-free conditions. C3H/HeOuJ mice were also bred under germ-free conditions. Mouse strains used in infection experiments were NrampS. B-Lag3 À/À mice were obtained by reconstituting recipient mice with a mixture of bone marrow cells from B cell-deficient J H T mice (80%) and Lag3 À/À mice (20%). Control B-WT chimera was obtained using a mixture of bone marrow cells from J H T mice (80%) and C57BL/6 mice (20%). B-Lag3 À/À Il10eGFP and their B-Il10eGFP controls were obtained using the same strategy. All experiments were reviewed and approved by appropriate institutional review committees (LAGeSo Berlin), and were conducted according to French, and German legislations, in compliance with European community council directive 68/609/EEC guidelines. Mice were of C57BL/6 strain, 6-14 weeks old at start of experiments, unless otherwise stated, and of sex-matched male and female genders.
METHOD DETAILS
Bacterial infection
Mice were infected with 1x10 6 or 1x10 7 CFU for Salmonella typhimurium SL7207 strain or 100 CFU for SL1344 strain intravenously (i.v.). For survival and vaccination plus rechallenge experiments mice were first vaccinated with 1x10 6 CFU of SL7207 given i.v. and 90 days later were rechallenged with 100 CFU of SL1344 or 1x10 6 or 10 7 CFU of SL7207. During survival experiments, mice were daily checked and presented as percentage of live animals. The bacterial loads were determined by plating a series of dilutions of homogenized organs on MacConkey agar plates. Heat-killed S. typhimurium (HKST) was prepared by inactivation of the SL1344 strain in water bath at 70 C for 1 hour. Bacteria were suspended in PBS. Salmonella infection was performed in a blinded manner, and identities of the mice were revealed upon termination of the experiment. No randomization was used. Estimation of size groups was based on our previous experience with these disease models, without a priori determination via power calculation. For neutralization of IL-10 signaling, mice were treated i.v. with a combination of anti-IL-10 (JES5-2A5; 500 mg/mouse/injection; BioXCell) and anti-IL-10R (1B1.3A; 500 mg/mouse/injection; BioXCell) on days À3, À1, and +1 after infection.
Tamoxifen administration
Tamoxifen was resuspended in sunflower seed oil from Helianthus annuus to a final concentration of 20mg/ml. 10mg of tamoxifen was administered by gavage to Aicda-cre-ERT2-ROSA-STOP-RFP mice twice with 5 days interval between the first and second administration. Mice were analyzed 15 days after the last administration.
Immunization and treatment with agonists of BCR, CD40, TLR4 C57BL/6 mice were immunized i.p. with 200 mg NP-KLH precipitated in alum, NP-Ficoll, or NP-LPS. Mice were analyzed 7 days after immunization. In house conjugated APC or PE nitrophenyl hapten was used to detected NP specific B and plasmocytes. Il10eGFP mice were injected i.v. with 100 mg anti-BCR (Fab2 anti-mouse IgM), 50 mg anti-CD40 (FGK-45), or 10 mg LPS (E. coli 055:B5), alone or in combination. Mice were analyzed 24h later.
Isolation of plasmocytes and B cells
For gene array, quantitative PCR, restimulation in vitro, ELISPOT assays and transmission electron microscopy analysis, plasmocytes and B cell subsets were obtained from C57BL/6 or Il10eGFP mice, naive or on day 1 p.i. with 10 7 CFU Salmonella (SL7207) by a two steps process. First, CD138 + cells were enriched by autoMACS after incubation with anti-CD138-PE followed by anti-PE microbeads. CD138 + cells obtained after autoMACS were then stained with anti-CD19, CD138, LAG-3, CD22 and CD11b/CD11c/ TCR-b/DAPI. The following populations were sorted by FACS Sorter Aria I and/or II from this fraction: CD138 hi CD22 + LAG-3 -CD11b -CD11c -TCRb -DAPI -, CD138 hi CD22 -LAG-3 -CD11b -CD11c -TCRb -DAPI -, CD138 hi CD22 -LAG-3 + CD11b -CD11c -TCRb -DAPI -, CD138 hi CD11b -CD11c -TCRb -DAPI -, CD138 hi Il10eGFP + CD11b -CD11c -TCR-b -DAPIand CD138 hi Il10eGFP -CD11b -CD11c -TCR-b -DAPI -, CD138 hi LAG-3 + CD11b -CD11c -TCR-b -DAPIand CD138 hi LAG-3 -CD11b -CD11c -TCR-b -DAPI -. The cells from the CD138-negative fraction after autoMACS were stained with anti-CD19, CD138, CD1d, CD21, CD23 and CD11b/CD11c/TCRb/DAPI. CD19 + CD138 -CD11b -CD11c -TCRb -DAPI -; CD19 + CD1d hi CD11b -CD11c -TCR-b -DAPIand CD19 + CD1d low CD11b -CD11c -TCR-b -DAPI -; CD19 + CD1d low CD21 + CD23 + CD11b -CD11c -TCRb -DAPI -(FO) and CD19 + CD1d high CD21 high CD23 low/-CD11b -CD11c -TCRb -DAPI -(MZ) were then isolated from this fraction by FACS Sorter Aria I and/or II. Total B cells were obtained by magnetic isolation using negative selection with anti-CD11b, CD11c, and CD43 microbeads. For PeC, cells were incubated with B-1a Cell Biotin-Antibody Cocktail (Miltenyli Biotec) for 5 minutes at 2-8 C and then with anti-Biotin Microbeads for an additional 10 minutes in the same conditions in order to deplete non-B cells, according to Manufacturer's instructions. LD columns were used for removing the non-B cells. Unlabeled cells were collected representing the pre-enriched B1a cell fraction that contained all PeC B cells fractions.
following forward (FP) and reverse (RP) primers (MWG Biotech): b-actin FP: 5 0 -TGGAATCCTGTGGCATCCATGAAAC-3 0 , b-actin RP: 5 0 -TAAAACGCAGCTCAGTAACAGTCC-3 0 ; IL-10 FP: 5 0 -AGCCGGGAAGACAATAAC TG-3 0 , IL-10 RP: 5 0 -CATTTCCGA TAAGGCTTG G-3 0 .
Ig gene amplification from single cells
Single cells sorted in 96-well PCR plate were immediately frozen on dry ice and stored at À80 C until further use. To amplify Ig gene from single cells, a nested PCR approach was used. Reverse transcription (RT) and the first PCR step for Igm (IgM) and Igk variable gene transcripts were carried out in a one-step reaction using the QIAGEN OneStep RT-PCR kit according to the manufacturer's instructions. The Ig gene primers were chosen based on Tiller et al. (2009) . The second round of PCR was carried out with 2ml of a 100-fold dilution of the unpurified first PCR product at 94 C for 4 minutes followed by 50 cycles of 94 C for 30 s, 60 C (Igm) or 48 C (Igk) for 30 s, 72 C for 45 s, and final incubation at 72 C for 10 minutes. The second PCR products were analyzed on 2% agarose gels.
The Ig gene PCR products from different plasmocyte subsets were sequenced (LGC) with the respective forward primers. Nucleotide sequences were then analyzed using IMGT/V-Quest to determine germline V, D, and J gene members, somatic hypermutation (counted for CDR1-FWR3 inclusively), CDR3 sequences, N-nucleotide addition.
Cloning of mouse Ig genes into expression vectors
After identifying V and J gene segment, second PCR reactions were repeated using 5ml of a 100-fold dilution of the unpurified first PCR product as template with specific V and J gene primers containing restriction sites to clone directly into expression vectors. PCR products were purified using Gel and PCR clean up kit before digestion with AgeI and SalI (Igh), AgeI and BsiWI (Igk). Digested Igh and Igk PCR products were purified from 0.9% agarose before ligation into expression vectors containing the human IGG1 and IGK constant regions, respectively. Ligation products were transformed into competent E.Coli via heat shock at 42 C, then E.Coli cells were plated on Ampicillin plates (100mg/ml) overnight at 37 C. Inserted genes were screened by PCR in Ampicillin resistant bacterial colonies.
Expression of recombinant immunoglobulin
Four single positively bacterial clones of each Igh and Igk gene were grown overnight at 37 C in 5ml of LB medium containing 100mg/ml Ampicillin. Plasmids were purified using NucleoSpin Plasmid -plasmid Miniprep kit (Macherey-Nagel), followed with digestion and analysis on 1% agarose. Inserted plasmids were then sequenced (GATC) to confirm identity with the second round PCR product and no mutation which probably is introduced by polymerase.
One day before transfection, 4x10 6 HEK293 T cells were plated in T175 culture flasks in complete DMEM (DMEM + 10% (v/v) FCS + Penicillin (100U/ml)/Streptomycin (100 mg/ml) + 2-Mercaptoethanol (50 mM). The cell should be 80% confluency on the day of transfection. Transient transfections were performed with calcium-phosphate precipitation. In brief, equal amounts of IgH (7mg) and corresponding IgK chain vector were mixed with sterile water and 124ml of 2M CaCl 2 . An equal volume of 1ml of 2X HBS was added drop-wise to the above mixture under slow vortexing and incubated at room temperature for 15min to allow formation of precipitates. The resulting solution was distributed to the culture flask. On the next day, cells were washed with 5ml of serum-free DMEM and 20ml of DMEM supplemented with 1% Nutridoma-SP, Penicillin (100U/ml)/Streptomycin (100 mg/ml) and 2-Mercaptoethanol (50 mM) was added. Supernatant were harvested at day 6 post transfection, cell debris was removed by centrifugation at 800 g for 10 minutes and culture supernatants were stored at À20 C.
Detection of antibody reactivity by ELISAs
IgG concentration in the supernatants were determined by ELISA. In brief, enhanced protein-binding ELISA plates were coated with 50ml of Goat Anti-Human IgG-UNLB diluted in carbonate buffer as capture antibody at 4 C overnight. Plates were washed 3 times with PBS. Unspecific binding was blocked by 200ml PBS/ 3%BSA for 1 hour at 37 C and washed again 4 times with PBS/0.1% Tween. Human IgG standard and culture supernatants were added, incubated for 2 hours at 37 C and washed again to remove unbound antibody with PBS/0.1% Tween. 100ml of Biotinylated Goat Anti-Human IgG Secondary Antibody was added, incubated for 1 hour at room temperature and washed again with PBS/0.1% Tween prior to adding ExtrAvidin Ò ÀPeroxidase for 1 hour at room temperature. After washing, assays were developed using 100ml TMB solution and incubated at RT for color development. Assays were stopped by H 2 SO 4 and ODs were measured at 450nm. Antibody concentration was determined by Softmax Pro software.
Antibodies with concentration higher than 5mg/ml were selected to test for polyreactivity with LPS, dsDNA and Insulin by ELISA. In brief, enhanced protein-binding ELISA plates were coated with 50ml of LPS (10mg/ml) or insulin (10mg/ml) or dsDNA (10mg/ml) in carbonate buffer and incubated at 4 C overnight. After washing, plates were incubated with 100ml nonpurified antibodies for 2 hours at 37 C and washed again. Nonpolyreactive (mGO53), low polyreactive (JB40), highly polyreactive (ED38) recombinant human monoclonal antibodies served as controls and were included on each plate. Unbound antibodies were removed by washing 4 times with PBS/0.1% Tween before detected using Biotinylated Goat Anti-Human IgG Secondary Antibody, followed with ExtrAvidin Ò ÀPeroxidase for 1 hour at room temperature. The rest steps were performed as above mentioned.
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